Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition.

ABSTRACT:

Background

Multiple myeloma (MM) is associated with a debilitating bone disease that poses significant therapeutic challenges. MM bone disease is characterized by increased bone resorption and suppression of osteoblasts, which hinders the repair of damaged bone. Sclerostin, an antagonist of Wnt signaling, is elevated in MM patients, and its inhibition with a neutralizing antibody (Scl-ab) has been shown to restore osteoblast function in mouse models of MM. However, it remains unclear whether Scl-ab can promote skeletal repair, enable effective tumor control when combined with anti-cancer agents, or improve bone health in MM patients.

Methods

To investigate these knowledge gaps, we used preclinical MM mouse models and patient-derived samples. We also characterize the impact o

SUBMITTER: Sabol HM 

PROVIDER: S-EPMC12372396 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature